Disclosures

Dr. Banaschewski has served as an advisor or consultant to Bristol-Myers Squibb, Desitin Arzneimittel, Eli Lilly, Medice, Novartis, Pfizer, Shire, UCB, and Vifor Pharma; he has received conference attendance support, conference support, or speaking fees from Eli Lilly, Janssen McNeil, Medice, Novartis, Shire, and UCB; and he is involved in clinical trials conducted by Eli Lilly, Novartis, and Shire; the present work is unrelated to these relationships. Dr Barker has received funding for a PhD student and honoraria for teaching on scanner programming courses from General Electric Healthcare; he acts as a consultant for IXICO. Dr Walter received a speaker honorarium from Servier (2014). The other authors report no biomedical financial interests or potential conflicts of interest.